Terms: = Pancreatic cancer AND CDK4, PSK-J3, 1019, ENSG00000135446, MGC14458, CMM3, P11802 AND Treatment
82 results:
1. cdk4/6 inhibition sensitizes MEK inhibition by inhibiting cell cycle and proliferation in pancreatic ductal adenocarcinoma.
Cheng K; Zhou Z; Chen Q; Chen Z; Cai Y; Cai H; Wu S; Gao P; Cai Y; Zhou J; Wang X; Wu Z; Peng B
Sci Rep; 2024 Apr; 14(1):8389. PubMed ID: 38600093
[TBL] [Abstract] [Full Text] [Related]
2. ER-positive and BRCA2-mutated breast cancer: a literature review.
Li PC; Zhu YF; Cao WM; Li B
Eur J Med Res; 2024 Jan; 29(1):30. PubMed ID: 38184581
[TBL] [Abstract] [Full Text] [Related]
3. SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma.
Man KF; Zhou L; Yu H; Lam KH; Cheng W; Yu J; Lee TK; Yun JP; Guan XY; Liu M; Ma S
Nat Commun; 2023 Nov; 14(1):7863. PubMed ID: 38030644
[TBL] [Abstract] [Full Text] [Related]
4. Combination therapy of niclosamide with gemcitabine inhibited cell proliferation and apoptosis via Wnt/β-catenin/c-Myc signaling pathway by inducing β-catenin ubiquitination in pancreatic cancer.
Kang HW; Kim JH; Lee DE; Lee YS; Kim MJ; Kim HS; Fang S; Lee BE; Lee KJ; Yoo J; Kim HJ; Park JS
Cancer Biol Ther; 2023 Dec; 24(1):2272334. PubMed ID: 37917550
[TBL] [Abstract] [Full Text] [Related]
5. The SGK3-Catalase antioxidant signaling axis drives cervical cancer growth and therapy resistance.
Wang M; Liu J; Liao X; Yi Y; Xue Y; Yang L; Cheng H; Liu P
Redox Biol; 2023 Nov; 67():102931. PubMed ID: 37866161
[TBL] [Abstract] [Full Text] [Related]
6. A real-world analysis of trametinib in combination with hydroxychloroquine or cdk4/6 inhibitor as third- or later-line therapy in metastatic pancreatic adenocarcinoma.
Tang H; Ge Y; You T; Li X; Wang Y; Cheng Y; Bai C
BMC Cancer; 2023 Oct; 23(1):958. PubMed ID: 37817078
[TBL] [Abstract] [Full Text] [Related]
7. Targeted inhibition of mTOR by BML-275 induces mitochondrial-mediated apoptosis and autophagy in prostate cancer.
Li W; Li D; Ma Q; Chen Y; Hu Z; Bai Y; Xie L
Eur J Pharmacol; 2023 Oct; 957():176035. PubMed ID: 37657741
[TBL] [Abstract] [Full Text] [Related]
8. E3 ligase MG53 suppresses tumor growth by degrading cyclin D1.
Fang M; Wu HK; Pei Y; Zhang Y; Gao X; He Y; Chen G; Lv F; Jiang P; Li Y; Li W; Jiang P; Wang L; Ji J; Hu X; Xiao RP
Signal Transduct Target Ther; 2023 Jul; 8(1):263. PubMed ID: 37414783
[TBL] [Abstract] [Full Text] [Related]
9. Molecular and Functional Heterogeneity of Primary pancreatic Neuroendocrine Tumors and Metastases.
Guo Y; Tian C; Cheng Z; Chen R; Li Y; Su F; Shi Y; Tan H
Neuroendocrinology; 2023; 113(9):943-956. PubMed ID: 37232011
[TBL] [Abstract] [Full Text] [Related]
10. Inhibiting cdk4/6 in pancreatic ductal adenocarcinoma via microRNA-21.
Mortoglou M; Miralles F; Mould RR; Sengupta D; Uysal-Onganer P
Eur J Cell Biol; 2023 Jun; 102(2):151318. PubMed ID: 37105116
[TBL] [Abstract] [Full Text] [Related]
11. A Preclinical and Phase Ib Study of Palbociclib plus Nab-Paclitaxel in Patients with Metastatic Adenocarcinoma of the Pancreas.
Hidalgo M; Garcia-Carbonero R; Lim KH; Messersmith WA; Garrido-Laguna I; Borazanci E; Lowy AM; Medina Rodriguez L; Laheru D; Salvador-Barbero B; Malumbres M; Shields DJ; Grossman JE; Huang X; Tammaro M; Martini JF; Yu Y; Kern K; Macarulla T
Cancer Res Commun; 2022 Nov; 2(11):1326-1333. PubMed ID: 36970055
[TBL] [Abstract] [Full Text] [Related]
12. First diagnosed invasive lobular carcinoma of the breast combined with gastric metastasis and bone metastasis: a case report and review of the literature.
Sun L; Liu J; Guo M; Xu J; Wang D
BMC Womens Health; 2023 Mar; 23(1):133. PubMed ID: 36966290
[TBL] [Abstract] [Full Text] [Related]
13. MYC-mediated resistance to trametinib and HCQ in PDAC is overcome by cdk4/6 and lysosomal inhibition.
Silvis MR; Silva D; Rohweder R; Schuman S; Gudipaty S; Truong A; Yap J; Affolter K; McMahon M; Kinsey C
J Exp Med; 2023 Mar; 220(3):. PubMed ID: 36719686
[TBL] [Abstract] [Full Text] [Related]
14. Combined inhibition of ACLY and cdk4/6 reduces cancer cell growth and invasion.
Velez BC; Petrella CP; DiSalvo KH; Cheng K; Kravtsov R; Krasniqi D; Krucher NA
Oncol Rep; 2023 Feb; 49(2):. PubMed ID: 36562384
[TBL] [Abstract] [Full Text] [Related]
15. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma.
Tong Y; Sun M; Chen L; Wang Y; Li Y; Li L; Zhang X; Cai Y; Qie J; Pang Y; Xu Z; Zhao J; Zhang X; Liu Y; Tian S; Qin Z; Feng J; Zhang F; Zhu J; Xu Y; Lou W; Ji Y; Zhao J; He F; Hou Y; Ding C
J Hematol Oncol; 2022 Nov; 15(1):168. PubMed ID: 36434634
[TBL] [Abstract] [Full Text] [Related]
16. Combination Therapies with cdk4/6 Inhibitors to Treat KRAS-Mutant pancreatic cancer.
Goodwin CM; Waters AM; Klomp JE; Javaid S; Bryant KL; Stalnecker CA; Drizyte-Miller K; Papke B; Yang R; Amparo AM; Ozkan-Dagliyan I; Baldelli E; Calvert V; Pierobon M; Sorrentino JA; Beelen AP; Bublitz N; Lüthen M; Wood KC; Petricoin EF; Sers C; McRee AJ; Cox AD; Der CJ
Cancer Res; 2023 Jan; 83(1):141-157. PubMed ID: 36346366
[TBL] [Abstract] [Full Text] [Related]
17. Synthesis and anti-tumor activity of nitrogen-containing derivatives of the natural product diphyllin.
Li Y; Lu Q; Xiao R; Ma J; Tang Y; Chen W; Zhang R; Jiang L; Chen H; Shen B; Zhang A; Ding C
Eur J Med Chem; 2022 Dec; 243():114708. PubMed ID: 36122549
[TBL] [Abstract] [Full Text] [Related]
18. Efficacy of open dialogue about complementary and alternative medicine compared with standard care in improving quality of life in patients undergoing conventional oncology treatment (CAMONCO 2): protocol for a randomised controlled trial.
Stie M; Delmar C; Nørgaard B; Jensen LH
BMJ Open; 2022 Apr; 12(4):e059960. PubMed ID: 35470199
[TBL] [Abstract] [Full Text] [Related]
19. Implication of ERBB2 as a Predictive Tool for Survival in Patients with pancreatic cancer in Histological Studies.
Ortega MA; Pekarek L; Fraile-Martinez O; Garcia-Montero C; Saez MA; Asúnsolo A; Alvarez-Mon MA; Monserrat J; Ruiz-Llorente L; García-Honduvilla N; Albillos A; Buján J; Alvarez-Mon M; Guijarro LG
Curr Oncol; 2022 Mar; 29(4):2442-2453. PubMed ID: 35448172
[TBL] [Abstract] [Full Text] [Related]
20. A Novel cdk4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin treatment in Breast and Ovarian cancer.
Tian C; Wei Y; Li J; Huang Z; Wang Q; Lin Y; Lv X; Chen Y; Fan Y; Sun P; Xiang R; Chang A; Yang S
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35270034
[TBL] [Abstract] [Full Text] [Related]
[Next]
